China Resources Jiangzhong Pharmaceutical Co (600750) Fair Value & Analysis
Healthcare · CN · Market cap 15.7B CNY
Analysis
China Resources Jiangzhong Pharmaceutical Co (600750) currently trades at ¥23.35, while our model-based Fair Value estimate is ¥27.84 — implying the stock looks roughly 19.2% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, fritillaria and loquat capsules, bezoar and snake gallbladder fritillaria liquid, and compound gold melon seed. It also provides health consumer and other products, such as nourishing, tonics, rehabilitation nutrition, gastrointestinal health, and liver health products. In addition, the company offers prescription drugs comprising traditional Chinese medicine products, which includes Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules; chemical medicine products, such as lumbrokinase enteric-coated capsules, Rabeprazole sodium enteric-coated tablets, chloroprocaine hydrochloride, etc.; and m…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.